La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aveanna Healthcare Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aveanna Healthcare Hldgs..

Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni, Catena delle Opzioni

Aveanna Healthcare Hldgs

Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is primarily derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Holdings Inc

Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.75) by 5.33 percent.

Earnings

Earnings Beats

News

RCKT

Rocket Pharmaceuticals Q3 2024 GAAP EPS $(0.71) Beats $(0.75) Estimate

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

Guidance

CYRX

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 22.22 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $250.885 million which missed the analyst consensus estimate of $252.108 million by 0.49 percent. This is a 4.85 percent increase over sales of $239.287 million the same period last year.

Earnings Misses

NVEE

NV5 Global Q3 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $250.885M Miss $252.108M Estimate

FRLA

Fortune Rise Acquisition Extends To Complete Business Combination From Nov. 5 To Dec. 5

WIIM

PRPH

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

MYGN

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

Buybacks

DVAX

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) raises FY2024 Adj EPS guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 analyst estimate. Raises FY2024 sales outlook from $145.00 million-147.80 million to $146.80 million-147.80 million vs $146.33 million estimate.

ONTF

ON24 Raises FY2024 Adj EPS Guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 Est; Raises FY2024 Sales Guidance from $145.00M-147.80M to $146.80M-147.80M vs $146.33M Est

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) affirms FY2024 sales outlook from $1.40 billion-1.60 billion to $1.40 billion-1.60 billion.

Bloom Energy Affirms FY2024 Sales Guidance to $1.40B-1.60B  VS Est.1.47B

Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 90 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.31 million by 49.24 percent. This is a 46.88 percent decrease over sales of $1.25 million the same period last year.

PHUN

Phunware Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $665.00K Miss $1.31M Estimate

Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $53.16 million which beat the analyst consensus estimate of $52.60 million by 1.06 percent. This is a 11.44 percent increase over sales of $47.70 million the same period last year.

Apartment Inv & Mgmt Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $53.16M Beat $52.60M Estimate

New facility will enable testing of liquid hydrogen (LH2), liquid oxygen (LOX) and liquid methane (LCH4)

Graham To Construct Cryogenic Propellant Testing Facility

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) is looking for Q4 Adj EPS of $0.01-0.02 vs $0.01 analyst estimate. sees sales of $35.400 million-36.400 million vs $35.87 million estimate.

ON24 Sees Q4 Adj EPS $0.01-0.02 vs $0.01 Est; Sees Sales $35.400M-36.400M vs $35.87M Est

MRVI

Maravai LifeSciences To Acquire Officinae Bio's DNA And RNA Business, Enhancing Nucleic Acid Research Capabilities; Acquisition To Boost Maravai's mRNA Manufacturing Through TriLink BioTechnologies

Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.06) by 550 percent. This is a 750 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $823.70 million which beat the analyst consensus estimate of $748.00 million by 10.12 percent.

LION

Lionsgate Studios Q2 2025 GAAP EPS $(0.39) Misses $(0.06) Estimate, Sales $823.70M Beat $748.00M Estimate

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) is looking for Q2 Adj EPS of $0.01-0.05 vs $0.10 analyst estimate. sees sales of $29.000 million-33.000 million vs $38.60 million estimate.

LTRX

Lantronix Sees Q2 Adj EPS $0.01-0.05 vs $0.10 Est; Sees Sales $29.000M-33.000M vs $38.60M Est

FIGS

FIGS shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 revenue guidance.

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is looking for Q4 Adj EPS of $0.47-0.52 vs $0.51 analyst estimate. seessales of $167.000 million-169.000 million vs $168.08 million estimate.

BlackLine Sees Q4 Adj EPS $0.47-0.52 vs $0.51 Est; Sees Sales $167.000M-169.000M vs $168.08M Est

Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) lowers FY2024 sales outlook from $380.00 million-420.00 million to $370.00 million-400.00 million.

ADEA

Adeia Lowers FY2024 Sales Guidance from $380.00M-420.00M to $370.00M-400.00M

Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.57) by 10.53 percent.

LBPH

Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate

An update from Aveanna Healthcare Holdings (AVAH) is now available. Aveanna Healthcare Holdings Inc. has released a financial presentation for inve...

Aveanna Healthcare Shares Investor Presentation Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Akebia Thera...

Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AMN Healthcare Services (AMN – Research Report), Verona Pharma (V...

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Verona Pharma (VRNA) and Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare files for $400M mixed securities shelf

Truist Financial analyst Jailendra Singh maintained a Hold rating on Aveanna Healthcare Holdings (AVAH – Research Report) today. The company's shar...

Truist Financial Keeps Their Hold Rating on Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare Holdings ( ($AVAH) ) has shared an update. Aveanna Healthcare has successfully amended its First Lien Credit Agreement, extendin...

Aveanna Healthcare Bolsters Liquidity with Credit Agreement Extension

Aveanna Healthcare Holdings ( ($AVAH) ) just unveiled an update. Aveanna Healthcare Holdings Inc. has appointed Brent Layton as a Class III directo...

Aveanna Healthcare Appoints Brent Layton to Board

The latest announcement is out from Aveanna Healthcare Holdings ( ($AVAH) ). Aveanna Healthcare Holdings reported robust financial growth for Q3 20...

Aveanna Healthcare Sees Revenue Growth Despite Net Loss

Reports Q3 revenue $509.0M, consensus $496.02M. CEO Jeff Shaner commented, "We have delivered another strong operating and financial quarter, highl...

Aveanna reports Q3 adjusted EPS 2c, consensus (1c)

Raises 2024 adjusted EBITDA view to greater than $168M from greater than $158M. Published first on TheFly – the ultimate source for real-time, mark...

Aveanna raises 2024 revenue view to $2.0B from above $1.985B, consensus $1.99B

AKBA

AVAH

GOVX

VRNA

Press Releases

Aveanna to Participate at the Barclays Leveraged Finance Conference

Aveanna Healthcare Holdings Announces First Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference

Aveanna Announces Second Quarter 2024 Earnings Release Date and Conference Call

Aveanna Healthcare Holdings Announces Second Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference

Aveanna Announces Third Quarter 2024 Earnings Release Date and Conference Call

Aveanna to Participate Virtually at the Stephens Annual Investment Conference

Management

Aveanna Healthcare Holdings Announces Appointment of New Director

Aveanna Healthcare Holdings Announces Third Quarter 2024 Financial Results and Revised 2024 Outlook

Accolade

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Fulgent Genetics

InnovAge Holding

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

National Research Corporation - Common Stock

National Research

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

Premier

Pennant Gr

Privia Health Gr

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

Talkspace

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

RBC Capital

Deutsche Bank

Credit Suisse

Truist Securities

Aveanna Healthcare Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 sales guidance above estimates.

Comments

Aveanna Healthcare Hldgs

Aveanna Healthcare Hldgs (AVAH) Opzioni

Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO